Zobrazeno 1 - 10
of 293
pro vyhledávání: '"FUMIHITO HIRAI"'
Autor:
Hiroshi Nakase, Kohei Wagatsuma, Taku Kobayashi, Takayuki Matsumoto, Motohiro Esaki, Kenji Watanabe, Reiko Kunisaki, Teruyuki Takeda, Katsuhiro Arai, Takashi Ibuka, Dai Ishikawa, Yuichi Matsuno, Hirotake Sakuraba, Nobuhiro Ueno, Kaoru Yokoyama, Masayuki Saruta, Ryota Hokari, Junji Yokoyama, Shu Tamano, Masanori Nojima, Tadakazu Hisamatsu, Shusaku Yoshikawa, Sohachi Nanjo, Akira Andoh, Takeshi Kimura, Makoto Ooi, Ryosuke Kiyomori, Nobuo Aoyama, Fumihito Hirai, Atsushi Yamaushi, Masanao Nakamura, Fumikazu Koyama, Shuhei Hosomi, Kazuki Kakimoto, Satoshi Motoya, Ryosuke Sakemi, Hideo Suzuki, Tadashi Hosoya, Ken Takeuchi, Manabu Shiraki, Hideyuki Koide, Ichiro Takeuchi, Yosuke Furui, Kento Yoshida, Ayaka Minemura, Asami Matsumoto, Kentaro Oka
Publikováno v:
EBioMedicine, Vol 110, Iss , Pp 105454- (2024)
Summary: Background: The involvement of Mediterranean fever (MEFV) gene mutations in patients with inflammatory bowel disease unclassified (IBDU) remains unclear. This study aimed to determine the clinical characteristics and responsiveness to colchi
Externí odkaz:
https://doaj.org/article/65aa18ec7b90480d9069fe49057c33ed
Autor:
Taku Kobayashi, Katsuyoshi Matsuoka, Mamoru Watanabe, Tadakazu Hisamatsu, Fumihito Hirai, Joe Milata, Xingyuan Li, Nathan Morris, Vipin Arora, Tomoko Ishizuka, Koji Matsuo, Yoichi Satoi, Catherine Milch, Toshifumi Hibi
Publikováno v:
Intestinal Research, Vol 22, Iss 2, Pp 172-185 (2024)
Background/Aims Mirikizumab is a p19-directed anti-interleukin-23 antibody with potential efficacy against ulcerative colitis (UC). We evaluated the efficacy and safety of mirikizumab in a Japanese subpopulation with moderately to severely active UC
Externí odkaz:
https://doaj.org/article/d73b47e8a614419ea0a3a92df36cd045
Autor:
Takehiko Koga, Naoaki Tsuchiya, Yusuke Ishida, Takanori Kitaguchi, Keisuke Matsumoto, Makoto Fukuyama, Satoki Kojima, Norihiro Kojima, Fumihito Hirai
Publikováno v:
Endoscopy International Open, Vol 12, Iss 05, Pp E666-E675 (2024)
Externí odkaz:
https://doaj.org/article/af249573236b43c18deb4e8574aee39d
Autor:
Takahiro Nagata, Sadahiro Funakoshi, Daisuke Morihara, Satoshi Shakado, Keiji Yokoyama, Kazuhide Takata, Takashi Tanaka, Atsushi Fukunaga, Ryo Yamauchi, Hiromi Fukuda, Hiroki Matsuoka, So Imakiire, Hideto Sakisaka, Satoshi Matsuoka, Nobuaki Kuno, Koichi Abe, Hideki Ishibashi, Shinya Ashizuka, Fumihito Hirai
Publikováno v:
Intestinal Research, Vol 21, Iss 4, Pp 471-480 (2023)
Background/Aims The frequency and details of nonalcoholic fatty liver disease (NAFLD) complications in patients with inflammatory bowel disease (IBD) remain unclear. This study aimed to clarify characteristics of NAFLD in patients with IBD. Methods W
Externí odkaz:
https://doaj.org/article/0429f6e39f5942fc842b4e1224e0fade
Autor:
Takashi Tanaka, Kazuhide Takata, Takashi Miyayama, Kumiko Shibata, Hiromi Fukuda, Ryo Yamauchi, Atsushi Fukunaga, Keiji Yokoyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Percutaneous radiofrequency ablation (RFA) is effective for the treatment of small hepatocellular carcinoma (HCC) with a diameter ≤ 3.0 cm. The present study aimed to elucidate the prognostic factors and clarify the indication of treatment
Externí odkaz:
https://doaj.org/article/d1d931430c5a49f79d79a9d8e504e8ff
Autor:
Hiroshi Nakase, Yuki Hayashi, Yoshihiro Yokoyama, Takayuki Matsumoto, Minoru Matsuura, Hideki Iijima, Katsuyoshi Matsuoka, Naoki Ohmiya, Shunji Ishihara, Fumihito Hirai, Daiki Abukawa, Tadakazu Hisamatsu, Makoto Sasaki, Masahiro Iizuka, Mikihiro Fujiya, Fukunori Kinjo, Shiro Nakamura, Noriko Kamata, Yuri Etani, Fumiaki Ueno, Sakiko Hiraoka, Takeo Kondo, Takashi Kagaya, Makoto Naganuma, Kiyonori Kobayashi, Taku Kobayashi, Shuji Yamamoto, Yuji Naito, Yoki Furuta, Keichi Mitsuyama, Yu Hashimoto, Katsuhiro Arai, Shingo Kato, Itaru Iwama, Motohiro Esaki, Hiroki Tanaka, Satoshi Motoya, Atsuo Maemoto, Toshifumi Ashida, Nobuaki Nishimata, Shigeaki Aono, Akira Andoh, Hironori Yamamoto, Toshiaki Shimizu, Maeda Yasuharu, Kenji Kinoshita, Katuyuki Fukuda, Jun Kato, Ken Takeuchi, Masakazu Nagahori, Masakatsu Fukuzawa, Masayuki Saruta, Takayoshi Suzuki, Michio Itabashi, Masaru Shinozaki, Soichiro Ishihara, Naoki Yoshimura, Yoichi Kakuta, Kenichi Takahashi, Keiichi Tominaga, Ryosuke Sakemi, Sohachi Nanjo, Shusaku Yoshikawa, Keiji Ozeki, Ayako Fuchigami, Takehiko Katsurada, Kenji Watanabe, Hirotake Sakuraba, Takashi Hisabe, Shigeru Iwase, Ryota Hokari, Katsuhiko Nakai, Takeshi Ueda, Shojiro Yamamoto, Kazutaka Koganei, Reiko Kunisaki, Akira Hokama
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 8, Pp 1056-1065 (2023)
Background and Aims: Japan has experienced 8 waves of the coronavirus disease 2019 (COVID-19) outbreak over the past 3 years, resulting in an increasing number of deaths and incidence of severe infections. This study aimed to analyze the data from th
Externí odkaz:
https://doaj.org/article/6dc0fa435835412099a962069329f0e1
Autor:
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, Mamoru Watanabe
Publikováno v:
Intestinal Research, Vol 21, Iss 1, Pp 110-125 (2023)
Background/Aims The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. Methods SELECTION (NCT02914522) was a
Externí odkaz:
https://doaj.org/article/d7f57edfaba24c2f9b5b590bd3380150
Autor:
Takashi Tanaka, Kazuhide Takata, Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Atsushi Fukunaga, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
Publikováno v:
Current Oncology, Vol 29, Iss 7, Pp 4799-4810 (2022)
Background: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as the first-line systemic therapy for patients with unresectable hepatocellular carcinoma (u-HCC). This study aimed to investigate the predictive factors of therapeutic re
Externí odkaz:
https://doaj.org/article/1362212f03c141aa96baebbf03864dea
Autor:
Eun Soo Kim, Chung Hyun Tae, Sung-Ae Jung, Dong Il Park, Jong Pil Im, Chang Soo Eun, Hyuk Yoon, Byung Ik Jang, Haruhiko Ogata, Kayoko Fukuhara, Fumihito Hirai, Kazuo Ohtsuka, Jing Liu, Qian Cao
Publikováno v:
Intestinal Research, Vol 20, Iss 2, Pp 192-202 (2022)
Background/Aims Complementary and alternative medicine (CAM) is prevalent in East Asia. However, information on CAM in East Asian patients with inflammatory bowel disease (IBD) is scarce. We aimed to profile the prevalence and pattern of CAM use amon
Externí odkaz:
https://doaj.org/article/689fc542c6b949238bb29ceb9b6bd479
Autor:
So Imakiire, Hidetoshi Takedatsu, Keiichi Mitsuyama, Hideto Sakisaka, Kozo Tsuruta, Masaru Morita, Nobuaki Kuno, Koichi Abe, Sadahiro Funakoshi, Hideki Ishibashi, Shinichiro Yoshioka, Takuji Torimura, Fumihito Hirai
Publikováno v:
Gut and Liver, Vol 16, Iss 1, Pp 92-100 (2022)
Background/Aims: Proteinase 3 antineutrophil cytoplasmic antibody (PR3-ANCA) is a serologic marker for granulomatosis with polyangiitis. However, recent studies have also shown their role as diagnostic markers for ulcerative colitis (UC). This study
Externí odkaz:
https://doaj.org/article/5cef46687ca4472b973f4438edab5aa6